🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Ningbo No. 1 Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Ningbo No. 1 Hospital as lead sponsor. Synced 26 Sep 2026
8Current trials
3Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Ningbo No. 1 Hospital is the lead sponsor of 8 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Not applicable. The most-studied condition is Metabolic Dysfunction-Associated Steatotic Liver Disease.

ClinicalTrials.gov trials by status

  • Recruiting338%
  • Not yet open113%
  • Active, closed338%
  • By invitation113%

Trials by phase

  • Not applicable563%
  • Observational225%
  • Phase 1113%
01

Clinical trials sponsored by Ningbo No. 1 Hospital

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
NCT06984510 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease, Biological Age
Observational Recruiting 2025-04 China
Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones
NCT06987760 · ClinicalTrials.gov ↗ · Ureter Injury, Urolithiasis; Lower Urinary Tract, Efficacy, Self
Not applicable Recruiting 2025-03 China
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
NCT05659628 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma
Phase 1 Recruiting 2022-12 China
Pre-procedural Risk Score-Based Endoscopist Assignment for Pain Reduction in Unsedated Colonoscopy
NCT07713953 · ClinicalTrials.gov ↗ · Colonoscopy Pain
Not applicable Not yet open 2026-07 China
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
NCT07001865 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity, Hyperuricemia
Observational By invitation 2025-04 China
Optimizing Intervention Effects in Children and Adolescents
NCT05482165 · ClinicalTrials.gov ↗ · Childhood Obesity
Not applicable Active, closed 2022-09 China
Healthy Weight Management Project for Overweight and Obesity Children
NCT05482191 · ClinicalTrials.gov ↗ · Obesity
Not applicable Active, closed 2022-09 China
Screening and Intervention of MASLD in Children
NCT06905795 · ClinicalTrials.gov ↗ · MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Children
Not applicable Active, closed 2025-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Ningbo No. 1 Hospital trials

14 conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease2Type 2 Diabetes Mellitus (T2DM)1Biological Age1Colonoscopy Pain1Childhood Obesity1Obesity1Metabolically Healthy Obesity1Hyperuricemia1MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease1Children1Ureter Injury1Urolithiasis; Lower Urinary Tract1Efficacy, Self1Diffuse Large B-cell Lymphoma1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China83

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Metabolic Dysfunction-Associated Steatotic Liver Disease

SponsorTrials
Xiamen Amoytop Biotech1
The Affiliated Hospital of Hangzhou Normal University1

Sponsors with the most current trials registered for this condition.

05

Questions about Ningbo No. 1 Hospital trials

How many clinical trials does Ningbo No. 1 Hospital sponsor?

Ningbo No. 1 Hospital is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Ningbo No. 1 Hospital trials recruiting?

Yes. 3 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.